Skip to main content
. 2016 Nov 30;8(2):3274–3288. doi: 10.18632/oncotarget.13712

Figure 2. The number of recognized Ag was significantly higher in patients with progressive CLL than in patients with stable disease.

Figure 2

The number of recognized Ag was correlated with parameters of disease progression collected at the time of SERPA. Disease progression was evaluated according to IWCLL/NCI-WG 2008 guidelines for CLL. Patients with progressive CLL (n=10) recognized a significantly higher number of spots compared to patients with stable CLL (n=22) (p=0.01). Box and whiskers plots represent median values, first and third quartiles, and minimum and maximum values for each dataset.